NCT04746768

Brief Summary

Decrease the prevalence of frailty syndrome in individuals with complete response of cancer.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started May 2021

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 26, 2020

Completed
3 months until next milestone

First Posted

Study publicly available on registry

February 10, 2021

Completed
3 months until next milestone

Study Start

First participant enrolled

May 4, 2021

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2023

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2024

Completed
Last Updated

June 8, 2021

Status Verified

February 1, 2021

Enrollment Period

1.7 years

First QC Date

November 26, 2020

Last Update Submit

June 3, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change of the prevalence of frailty syndrome in individuals with complete response of cancer

    evolution of individual frailty during a multimodal intervention (physical and nutritional activity) according to the Fried's criteria

    0, 6 and 12 months

Secondary Outcomes (8)

  • evaluation of predicitive variables of frailty syndrome reversion

    Month 0, 6 and 12

  • Correlations between physical performance and frailty syndrome and their evolutions

    Month 0, 6 and 12

  • Change from baseline nutritional status during nutritionist support (month 3 and 6) and at the end of empowerment (month 12)

    Month 0, 3, 6 and 12

  • Measure adherence to APA interventions and exercise practices

    between month 1 to 6 and between month 6 to 12

  • Estimation of adherence to nutritional interventions

    Month 6 and 12

  • +3 more secondary outcomes

Study Arms (1)

exercise and nutritional support

EXPERIMENTAL

exercise and nutritional support program during an active support phase (0 to 6 months) followed by an empowerment phase (from 6 to 12 months)

Combination Product: exercise and nutritional support

Interventions

exercise and nutritional support program during an active support phase (0 to 6 months) followed by an empowerment phase (from 6 to 12 months)

exercise and nutritional support

Eligibility Criteria

Age70 Years+
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)

You may qualify if:

  • in complete remission from cancer (all type of cancer)
  • have a frailty syndrome (positive GFST score)
  • ability to provide signed informed consent
  • be affiliated with social security or beneficiary of such a scheme

You may not qualify if:

  • patient with active cancer or any other pathology affecting the prognosis at 5 years
  • subjects referred to articles L1121-5 to L1121-8 of CSP (corresponds to all protected persons: person deprived of liberty by judicial or administrative decision, person subject to legal protection measure)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU de Grenoble

Grenoble, France

RECRUITING

MeSH Terms

Conditions

FrailtyMotor ActivityNeoplasms

Interventions

ExerciseNutritional Support

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and SymptomsBehavior

Intervention Hierarchy (Ancestors)

Motor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological PhenomenaNutrition TherapyTherapeutics

Study Officials

  • Gaëtan Gavazzi, MD, PhD

    University Hospital, Grenoble

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Gaëtan Gavazzi, MD, PhD

CONTACT

Stéphane Mouret, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 26, 2020

First Posted

February 10, 2021

Study Start

May 4, 2021

Primary Completion

January 1, 2023

Study Completion

January 1, 2024

Last Updated

June 8, 2021

Record last verified: 2021-02

Locations